JP2013050457A - 卵巣癌を判定するためのhe4及び他の生化学マーカーの使用 - Google Patents
卵巣癌を判定するためのhe4及び他の生化学マーカーの使用 Download PDFInfo
- Publication number
- JP2013050457A JP2013050457A JP2012226640A JP2012226640A JP2013050457A JP 2013050457 A JP2013050457 A JP 2013050457A JP 2012226640 A JP2012226640 A JP 2012226640A JP 2012226640 A JP2012226640 A JP 2012226640A JP 2013050457 A JP2013050457 A JP 2013050457A
- Authority
- JP
- Japan
- Prior art keywords
- patient
- marker
- ovarian cancer
- markers
- he4a
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010033128 Ovarian cancer Diseases 0.000 title claims abstract description 67
- 206010061535 Ovarian neoplasm Diseases 0.000 title claims abstract description 64
- 239000003550 marker Substances 0.000 claims abstract description 54
- 101000623901 Homo sapiens Mucin-16 Proteins 0.000 claims abstract description 51
- 101001024605 Homo sapiens Next to BRCA1 gene 1 protein Proteins 0.000 claims abstract description 50
- 238000011282 treatment Methods 0.000 claims abstract description 23
- 102100028186 ATP-binding cassette sub-family C member 5 Human genes 0.000 claims abstract 8
- 101710150022 ATP-binding cassette sub-family C member 5 Proteins 0.000 claims abstract 8
- 206010028980 Neoplasm Diseases 0.000 claims description 73
- 238000011462 intraperitoneal chemotherapy Methods 0.000 claims description 4
- 230000004044 response Effects 0.000 claims description 3
- 230000002829 reductive effect Effects 0.000 claims description 2
- 238000000034 method Methods 0.000 abstract description 91
- 206010034260 pelvic mass Diseases 0.000 abstract description 4
- 230000003247 decreasing effect Effects 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 89
- 102000004196 processed proteins & peptides Human genes 0.000 description 84
- 229920001184 polypeptide Polymers 0.000 description 79
- 239000000427 antigen Substances 0.000 description 52
- 108091007433 antigens Proteins 0.000 description 52
- 102000036639 antigens Human genes 0.000 description 52
- 201000011510 cancer Diseases 0.000 description 43
- 210000004027 cell Anatomy 0.000 description 41
- 102100038965 WAP four-disulfide core domain protein 2 Human genes 0.000 description 38
- 239000000523 sample Substances 0.000 description 38
- 201000010099 disease Diseases 0.000 description 30
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 30
- 210000002966 serum Anatomy 0.000 description 24
- 230000003211 malignant effect Effects 0.000 description 23
- 230000027455 binding Effects 0.000 description 22
- 108090000623 proteins and genes Proteins 0.000 description 22
- 239000012472 biological sample Substances 0.000 description 16
- 210000001124 body fluid Anatomy 0.000 description 15
- 238000001514 detection method Methods 0.000 description 15
- 230000035945 sensitivity Effects 0.000 description 15
- 238000003556 assay Methods 0.000 description 13
- 201000009030 Carcinoma Diseases 0.000 description 12
- 102000004169 proteins and genes Human genes 0.000 description 12
- 102000003735 Mesothelin Human genes 0.000 description 11
- 108090000015 Mesothelin Proteins 0.000 description 11
- 206010014759 Endometrial neoplasm Diseases 0.000 description 10
- 238000012216 screening Methods 0.000 description 10
- 210000001519 tissue Anatomy 0.000 description 10
- 239000010839 body fluid Substances 0.000 description 9
- 239000012530 fluid Substances 0.000 description 9
- 239000000463 material Substances 0.000 description 9
- 238000001356 surgical procedure Methods 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 210000002700 urine Anatomy 0.000 description 9
- 238000003745 diagnosis Methods 0.000 description 8
- 230000014509 gene expression Effects 0.000 description 8
- 239000007787 solid Substances 0.000 description 8
- 206010014733 Endometrial cancer Diseases 0.000 description 7
- 150000001413 amino acids Chemical group 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 7
- 230000000890 antigenic effect Effects 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 230000036210 malignancy Effects 0.000 description 7
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 6
- 206010058897 Adnexa uteri mass Diseases 0.000 description 6
- 108091028043 Nucleic acid sequence Proteins 0.000 description 6
- 239000003153 chemical reaction reagent Substances 0.000 description 6
- 239000012634 fragment Substances 0.000 description 6
- 150000007523 nucleic acids Chemical group 0.000 description 6
- 210000000056 organ Anatomy 0.000 description 6
- 239000000439 tumor marker Substances 0.000 description 6
- 108010022366 Carcinoembryonic Antigen Proteins 0.000 description 5
- 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 description 5
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 5
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 5
- BKAYIFDRRZZKNF-VIFPVBQESA-N N-acetylcarnosine Chemical compound CC(=O)NCCC(=O)N[C@H](C(O)=O)CC1=CN=CN1 BKAYIFDRRZZKNF-VIFPVBQESA-N 0.000 description 5
- 102000004264 Osteopontin Human genes 0.000 description 5
- 108010081689 Osteopontin Proteins 0.000 description 5
- 230000004927 fusion Effects 0.000 description 5
- 108020001507 fusion proteins Proteins 0.000 description 5
- 102000037865 fusion proteins Human genes 0.000 description 5
- 210000004408 hybridoma Anatomy 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 108010088201 squamous cell carcinoma-related antigen Proteins 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 4
- 206010035226 Plasma cell myeloma Diseases 0.000 description 4
- 239000002299 complementary DNA Substances 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 201000000050 myeloid neoplasm Diseases 0.000 description 4
- 230000001575 pathological effect Effects 0.000 description 4
- 230000009257 reactivity Effects 0.000 description 4
- 108010059616 Activins Proteins 0.000 description 3
- 102000005606 Activins Human genes 0.000 description 3
- 102100024321 Alkaline phosphatase, placental type Human genes 0.000 description 3
- 108060003951 Immunoglobulin Proteins 0.000 description 3
- 108010004250 Inhibins Proteins 0.000 description 3
- 102000002746 Inhibins Human genes 0.000 description 3
- 108010063954 Mucins Proteins 0.000 description 3
- 102000015728 Mucins Human genes 0.000 description 3
- 239000000488 activin Substances 0.000 description 3
- 229960002685 biotin Drugs 0.000 description 3
- 235000020958 biotin Nutrition 0.000 description 3
- 239000011616 biotin Substances 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 201000010063 epididymitis Diseases 0.000 description 3
- 230000003053 immunization Effects 0.000 description 3
- 102000018358 immunoglobulin Human genes 0.000 description 3
- 239000000893 inhibin Substances 0.000 description 3
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 239000006193 liquid solution Substances 0.000 description 3
- 238000007477 logistic regression Methods 0.000 description 3
- 210000004379 membrane Anatomy 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 210000005033 mesothelial cell Anatomy 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 210000003097 mucus Anatomy 0.000 description 3
- 230000002611 ovarian Effects 0.000 description 3
- 108010031345 placental alkaline phosphatase Proteins 0.000 description 3
- 210000002381 plasma Anatomy 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 238000011895 specific detection Methods 0.000 description 3
- 210000004989 spleen cell Anatomy 0.000 description 3
- 238000010561 standard procedure Methods 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 108010030690 tissue polypeptide specific antigen Proteins 0.000 description 3
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 229930186217 Glycolipid Natural products 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- 101000576802 Homo sapiens Mesothelin Proteins 0.000 description 2
- 108010058683 Immobilized Proteins Proteins 0.000 description 2
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 2
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 2
- RMINQIRDFIBNLE-NNRWGFCXSA-N O-[N-acetyl-alpha-neuraminyl-(2->6)-N-acetyl-alpha-D-galactosaminyl]-L-serine Chemical compound O1[C@H](OC[C@H](N)C(O)=O)[C@H](NC(=O)C)[C@@H](O)[C@@H](O)[C@H]1CO[C@@]1(C(O)=O)O[C@@H]([C@H](O)[C@H](O)CO)[C@H](NC(C)=O)[C@@H](O)C1 RMINQIRDFIBNLE-NNRWGFCXSA-N 0.000 description 2
- 206010058823 Ovarian mass Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 210000000683 abdominal cavity Anatomy 0.000 description 2
- 238000001042 affinity chromatography Methods 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 210000003567 ascitic fluid Anatomy 0.000 description 2
- 239000012620 biological material Substances 0.000 description 2
- 239000000090 biomarker Substances 0.000 description 2
- 238000001574 biopsy Methods 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 2
- 210000003756 cervix mucus Anatomy 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000002790 cross-validation Methods 0.000 description 2
- 208000031513 cyst Diseases 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- 230000002357 endometrial effect Effects 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 210000004251 human milk Anatomy 0.000 description 2
- 235000020256 human milk Nutrition 0.000 description 2
- 210000004754 hybrid cell Anatomy 0.000 description 2
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000002751 lymph Anatomy 0.000 description 2
- 206010061289 metastatic neoplasm Diseases 0.000 description 2
- 238000012775 microarray technology Methods 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 2
- 230000036963 noncompetitive effect Effects 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 210000003516 pericardium Anatomy 0.000 description 2
- 210000004303 peritoneum Anatomy 0.000 description 2
- 210000004224 pleura Anatomy 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000004393 prognosis Methods 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 238000003127 radioimmunoassay Methods 0.000 description 2
- 125000006853 reporter group Chemical group 0.000 description 2
- 210000003296 saliva Anatomy 0.000 description 2
- 230000003248 secreting effect Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000009870 specific binding Effects 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 210000001138 tear Anatomy 0.000 description 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 2
- 241001515965 unidentified phage Species 0.000 description 2
- 238000002562 urinalysis Methods 0.000 description 2
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 description 1
- TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 101710132601 Capsid protein Proteins 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 201000005171 Cystadenoma Diseases 0.000 description 1
- 206010058314 Dysplasia Diseases 0.000 description 1
- 241000724791 Filamentous phage Species 0.000 description 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101001133056 Homo sapiens Mucin-1 Proteins 0.000 description 1
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 208000030070 Malignant epithelial tumor of ovary Diseases 0.000 description 1
- 206010027304 Menopausal symptoms Diseases 0.000 description 1
- 206010027406 Mesothelioma Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 102100034256 Mucin-1 Human genes 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 101710188688 Non-structural protein 7a Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 208000007571 Ovarian Epithelial Carcinoma Diseases 0.000 description 1
- 206010061328 Ovarian epithelial cancer Diseases 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 108010010974 Proteolipids Proteins 0.000 description 1
- 102000016202 Proteolipids Human genes 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 108091002660 WAP Four-Disulfide Core Domain Protein 2 Proteins 0.000 description 1
- 102000021095 WAP Four-Disulfide Core Domain Protein 2 Human genes 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 229960003896 aminopterin Drugs 0.000 description 1
- 238000002820 assay format Methods 0.000 description 1
- 238000000376 autoradiography Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000007910 cell fusion Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 238000000546 chi-square test Methods 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 238000012875 competitive assay Methods 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 239000012531 culture fluid Substances 0.000 description 1
- 208000007321 cystadenofibroma Diseases 0.000 description 1
- 230000002498 deadly effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 210000004696 endometrium Anatomy 0.000 description 1
- 230000009144 enzymatic modification Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 210000000918 epididymis Anatomy 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000011152 fibreglass Substances 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000000951 immunodiffusion Effects 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 208000014699 malignant epithelioid mesothelioma Diseases 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 210000003593 megakaryocyte Anatomy 0.000 description 1
- 230000034217 membrane fusion Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 238000002324 minimally invasive surgery Methods 0.000 description 1
- 229940051875 mucins Drugs 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000013618 particulate matter Substances 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 210000003200 peritoneal cavity Anatomy 0.000 description 1
- 238000002823 phage display Methods 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000003345 scintillation counting Methods 0.000 description 1
- 239000006152 selective media Substances 0.000 description 1
- 238000010206 sensitivity analysis Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000004911 serous fluid Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 238000009331 sowing Methods 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 238000012285 ultrasound imaging Methods 0.000 description 1
- 229940116269 uric acid Drugs 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 238000001086 yeast two-hybrid system Methods 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57442—Specifically defined cancers of the uterus and endometrial
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57449—Specifically defined cancers of ovaries
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
Abstract
【解決手段】治療期間中の異なる時間で前記患者から得られた検体において、HE4マーカーと、SMRP、CA125及びCA72−4からなる群から選択された別のマーカーとの両方を含む少なくとも2つのマーカーで判定する工程を有するものであり、後半時における前記マーカーの減少した値は、前記患者がその治療に対して反応していることを示す。
【選択図】なし
Description
表1は、設定特異度レベルで使用されたマーカーの感受性の比較をまとめた実施例1の結果を含むものである。
本明細書で使用された「サンプル」という用語は、患者に特異的に関連し、そこから前記患者に関する特定の情報を決定、計算或いは推定することができる材料を意味している。サンプルは、前記患者からの生物学的材料の全部或いは一部で構成されている。サンプルは、前記患者に関する情報を提供する前記サンプル上でテストを行うことが可能な方法で前記患者に密着した材料であっても良い。サンプルは、前記患者のではないが、前記第一の材料によって前記患者に関する情報を決定するためにテストすることが可能である他の材料に密着した材料も可能である。サンプルは、当業者が前記サンプルから前記患者に関する情報を決定することができないという条件で、前記患者以外の生物学的材料の原料と接触できる。前記サンプルでない外来性材料或いは情報は、前記患者と前記サンプルを確証的に連結するために使用され得るということも理解される。限定されない実施例に対して、二重盲検テストは、サンプルと患者をマッチングするためのチャート或いはデータベースを必要とする。
卵巣癌は、婦人科悪性腫瘍の最も致死的なものである。22,000人以上の女性が診断を受け、2005年では16,000人がその病気で死んでいると見積もられている(Murray et al.,2005.Ca.Cancer.J.Clin.2005;55(1):10−30)。これらの女性の大部分は上腹部における疾患の証拠がある若しくはなく付属器腫瘤を発症している。しかしながら、米国の全女性の20パーセントは、ある時点で付属器腫瘤或いは嚢胞と診断され、彼らの数%が悪性腫瘍を示した。
一般的な方法
実施例において使用される標準組換えDNA及び分子クローニング技術は、当業者にはよく知られており、Sambrook,J.,Fritsch,E.F.and Maniatis,T.Molecular Cloning:A Laboratory Manual;Cold Spring Harbor Laboratory Press:Cold Spring Harbor,(1989)(Maniatis)、及びT.J.Silhavy,M.L.Bennan,and L.W.Enquist,Experiments with Gene Fusions,Cold Spring Harbor Laboratory,Cold Spring Harbor,N.Y.(1984)、及びAusubel,F.M.et al.,Current Protocols in Molecular Biology,pub.by Greene Publishing Assoc.and Wiley−Interscience (1987)に記載されている。
米国の全女性の20%は、付属器腫瘤或いは嚢胞と診断され、その中の数パーセントは悪性を示すものである。卵巣癌は外科的に病期診断され、研究によって婦人科腫瘍医によって手術された患者はしばしば、非婦人科腫瘍医によって手術された患者と比較してより適切に病期診断され手術される。CA125腫瘍マーカーは、骨盤腔内腫瘤を有する患者が卵巣癌を発症していることを予想するのに役立てることができる。しかしながら、多くの良性婦人科状態もCA125が上昇し、その特異性が減少している。この疾患の治療に熟達したセンターへこれら患者をトリアージするのを助けるためにより正確なテストが必要とされている。このアプローチはいくつかの新規腫瘍マーカーを適用し、卵巣癌のリスクを予測し且つ骨盤腔内腫瘤を有する患者を婦人科腫瘍医へトリアージするのを助けるために複数マーカーアッセイを開発した。
Claims (16)
- 卵巣癌を発症した患者の治療に対する反応を判定するためのHE4の使用であって、前記使用は、治療期間中の異なる時間で前記患者から得られた検体において、HE4マーカーと、SMRP、CA125及びCA72−4からなる群から選択された別のマーカーとの両方を含む少なくとも2つのマーカーで判定する工程を有するものであり、後半時における前記マーカーの減少した値は、前記患者がその治療に対して反応していることを示すものである、使用。
- 請求項1記載の使用であって、前記使用は、前記HE4及びCA125マーカーを判定する工程を有するものである、使用。
- 請求項1記載の使用であって、前記使用は、前記HE4及びSMRPマーカーを判定する工程を有するものである、使用。
- 請求項1記載の使用において、前記治療は腹腔内化学療法である、使用。
- 請求項1記載の使用において、前記治療はCA125に特異的に結合する抗体を患者に投与する工程を有するものである、使用。
- 卵巣癌の治療を受けている患者において再発を判定するためのHE4の使用であって、前記使用は、治療後の前記患者から採取された検体において、HE4マーカーと、SMRP、CA125及びCA72−4からなる群から選択された別のマーカーとの両方を含む少なくとも2つのマーカーで判定する工程を有するものであり、前記マーカーの上昇した値は、卵巣癌が前記患者において再発したことを示すものである、使用。
- 請求項6記載の使用において、前記マーカーは前記治療後に複数回判定されるものであり、前記マーカーの上昇した値は、卵巣癌が前記患者において再発したことを示すものである、使用。
- 請求項6記載の使用であって、前記使用は、前記HE4及びCA125マーカーを判定する工程を有するものである、使用。
- 請求項6記載の使用であって、前記使用は、前記HE4及びSMRPマーカーを判定する工程を有するものである、使用。
- 請求項6記載の使用において、前記治療は腹腔内化学療法である、使用。
- 請求項6記載の使用において、前記治療は、CA125に特異的に結合する抗体を患者に投与する工程を有するものである、使用。
- 患者が卵巣癌を発症する可能性を判定するためのHE4の使用であって、前記使用は、前記患者から採取した検体において、HE4マーカーと、SMRP、CA125及びCA72−4からなる群から選択された別のマーカーとの両方を含む少なくとも2つのマーカーで判定する工程を有するものであり、前記マーカーの上昇した値は、前記患者が卵巣癌を発症する可能性の増加に相関するものである、使用。
- 請求項12記載の使用であって、前記使用は、前記HE4及びCA125マーカーを判定する工程を有するものである、使用。
- 請求項13記載の使用において、前記患者はCA125マーカーの正常値を示し、前記HE4マーカーの上昇した値は、前記患者が卵巣癌を発症する可能性の増加に相関するものである、使用。
- 請求項12記載の使用であって、前記使用は、前記HE4及びSMRPマーカーを判定する工程を有するものである、使用。
- 卵巣癌を発症した患者における腫瘍を格付けするためのHE4の使用であって、前記使用は、前記患者から採取した検体において、HE4マーカーと、SMRP、CA125及びCA72−4からなる群から選択された別のマーカーとの両方を含む少なくとも2つのマーカーで判定する工程を有するものであり、前記マーカーの上昇した値は、卵巣癌のより高い格付けに相関するものである、使用。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US75613106P | 2006-01-04 | 2006-01-04 | |
US60/756,131 | 2006-01-04 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2008549563A Division JP5221381B2 (ja) | 2006-01-04 | 2007-01-04 | 卵巣癌を判定するためのhe4及び他の生化学マーカーの使用 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2013050457A true JP2013050457A (ja) | 2013-03-14 |
JP5711196B2 JP5711196B2 (ja) | 2015-04-30 |
Family
ID=38256906
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2008549562A Active JP5164855B2 (ja) | 2006-01-04 | 2007-01-04 | 子宮内膜または子宮癌を評価するためのhe4及びそのほかの生化学的マーカーの使用 |
JP2008549563A Active JP5221381B2 (ja) | 2006-01-04 | 2007-01-04 | 卵巣癌を判定するためのhe4及び他の生化学マーカーの使用 |
JP2012226640A Active JP5711196B2 (ja) | 2006-01-04 | 2012-10-12 | 卵巣癌を判定するためのhe4及び他の生化学マーカーの使用 |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2008549562A Active JP5164855B2 (ja) | 2006-01-04 | 2007-01-04 | 子宮内膜または子宮癌を評価するためのhe4及びそのほかの生化学的マーカーの使用 |
JP2008549563A Active JP5221381B2 (ja) | 2006-01-04 | 2007-01-04 | 卵巣癌を判定するためのhe4及び他の生化学マーカーの使用 |
Country Status (8)
Country | Link |
---|---|
US (6) | US20070286865A1 (ja) |
EP (6) | EP2423321A3 (ja) |
JP (3) | JP5164855B2 (ja) |
CN (3) | CN106124765A (ja) |
ES (2) | ES2650244T3 (ja) |
HK (1) | HK1219514A1 (ja) |
PL (1) | PL2982761T3 (ja) |
WO (2) | WO2007081768A2 (ja) |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000076011A2 (en) * | 1999-06-09 | 2000-12-14 | Moltech Corporation | Methods of preparing a microporous article |
US7270960B2 (en) | 2001-08-29 | 2007-09-18 | Pacific Northwest Research Institute | Diagnosis of ovarian carcinomas |
US20090075305A1 (en) * | 2005-05-02 | 2009-03-19 | The Brigham And Womern's Hospital, Inc. | Diagnostic serum antibody profiling |
WO2007081768A2 (en) * | 2006-01-04 | 2007-07-19 | Fujirebio America, Inc. | Use of he4 and other biochemical markers for assessment of ovarian cancers |
US20070212721A1 (en) * | 2006-01-27 | 2007-09-13 | Tripath Imaging, Inc. | Methods for identifying patients with an increased likelihood of having ovarian cancer and compositions therefor |
WO2008049239A1 (en) | 2006-10-27 | 2008-05-02 | Mount Sinai Hospital | Endometrial biomarkers |
WO2008112514A1 (en) * | 2007-03-09 | 2008-09-18 | Tripath Imaging, Inc. | He4 monoclonal antibodies and methods for their use |
JP5144742B2 (ja) * | 2007-03-29 | 2013-02-13 | フジレビオ ダイアグノスティックス インコーポレイテッド | 乳がんの評価のためのhe4の使用 |
CN101377502A (zh) * | 2007-08-31 | 2009-03-04 | 北京科美东雅生物技术有限公司 | 肿瘤相关抗原72-4化学发光免疫分析测定试剂盒及其制备方法 |
WO2009099561A2 (en) * | 2008-01-31 | 2009-08-13 | The Brigham And Womens' Hospital, Inc. | Urinary ca125 peptides as biomarkers of ovarian cancer |
US8476026B2 (en) * | 2008-04-01 | 2013-07-02 | The Brigham And Women's Hospital, Inc. | Biomarkers of ovarian cancer |
US20130224772A1 (en) * | 2010-08-26 | 2013-08-29 | University Of Washington Through Its Center For Commercialization | Method for detecting anti-he4 antibodies and methods of diagnosis and/or prognosis of conditions associated with he4-expressing cells |
KR20200013118A (ko) | 2011-02-17 | 2020-02-05 | 후지레비오 다이어그노스틱스, 인코포레이티드 | HE4a의 결정을 위해 사용되는 조성물들 및 방법들 |
CA2828119A1 (en) * | 2011-02-24 | 2012-08-30 | Vermillion, Inc. | Biomarker panels, diagnostic methods and test kits for ovarian cancer |
CN102735840B (zh) * | 2011-04-13 | 2014-06-04 | 中国医学科学院肿瘤研究所 | 用于诊断或筛查卵巢癌的试剂 |
WO2012170513A2 (en) * | 2011-06-06 | 2012-12-13 | Women & Infants' Hospital Of Rhode Island | He4 based therapy for malignant disease |
DE102012205164B4 (de) | 2012-03-29 | 2021-09-09 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Projektionsdisplay und Verfahren zur Projektion virtueller Bilder |
CN103575902B (zh) * | 2012-08-03 | 2015-07-29 | 河南生生医疗器械有限公司 | 一种时间分辨荧光法四项综合检测卵巢癌试剂盒及其应用 |
CN102890083B (zh) * | 2012-09-28 | 2016-08-10 | 辽宁科骏生物有限公司 | 化学发光底物溶液和含其的试剂盒及应用其的检测方法 |
CN104655858B (zh) * | 2015-03-12 | 2016-02-10 | 德迈基生物技术(北京)有限公司 | 定量检测人附睾分泌蛋白-4的荧光免疫层析试剂盒及其制备方法 |
CA2981068C (en) | 2015-03-26 | 2021-12-14 | Women & Infants Hospital Of Rhode Island | Therapy for malignant disease comprising the inhibition of human epididymal secretory protein e4 and immune checkpoint inhibitors |
RU2585959C1 (ru) * | 2015-06-22 | 2016-06-10 | Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский онкологический институт" Министерства здравоохранения Российской Федерации | Способ дифференциальной диагностики асцитно-инфильтративной формы рака яичников и абдоминального туберкулёза |
US10267802B2 (en) | 2015-09-23 | 2019-04-23 | The Board Of Trustees Of The Leland Stanford Junior University | Methods of prognosis and diagnosis of ovarian cancer |
RU2624508C1 (ru) * | 2016-06-29 | 2017-07-04 | Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский онкологический институт" Министерства здравоохранения Российской Федерации | Способ прогнозирования длительности ремиссии у больных раком вульвы |
WO2018009811A1 (en) | 2016-07-08 | 2018-01-11 | Genentech, Inc. | Use of human epididymis protein 4 (he4) for assessing responsiveness of muc 16-positive cancer treatment |
CA3175499A1 (en) | 2020-04-21 | 2021-10-28 | University Of Rochester | Inhibitors of human epididymus protein 4 |
CN111781364B (zh) * | 2020-08-25 | 2023-07-21 | 北京信诺卫康科技有限公司 | Wnt7a和HE4联合用作早期卵巢癌生物标志物以及试剂盒 |
WO2023195628A1 (ko) * | 2022-04-08 | 2023-10-12 | 아주대학교산학협력단 | Ca125 검출용 펩타이드 및 그 용도 |
WO2023195629A1 (ko) * | 2022-04-08 | 2023-10-12 | 아주대학교산학협력단 | He4 검출용 펩타이드 및 그 용도 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2005501549A (ja) * | 2001-08-29 | 2005-01-20 | パシフィック ノースウエスト リサーチ インスティテュート | 癌腫の診断 |
JP2006515065A (ja) * | 2002-08-16 | 2006-05-18 | ディシジョン バイオマーカーズ インコーポレイテッド | 蛍光配列の読み取り |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4816567A (en) * | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
CA1289880C (en) * | 1985-12-06 | 1991-10-01 | Jeffrey L. Winkelhake | Anti-human ovarian cancer immunotoxins and methods of use thereof |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
JPH02500329A (ja) | 1987-05-21 | 1990-02-08 | クリエイテイブ・バイオマリキユールズ・インコーポレーテツド | ターゲット化多機能蛋白質 |
US5091513A (en) * | 1987-05-21 | 1992-02-25 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
US5132405A (en) | 1987-05-21 | 1992-07-21 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5283173A (en) | 1990-01-24 | 1994-02-01 | The Research Foundation Of State University Of New York | System to detect protein-protein interactions |
US6998106B1 (en) * | 1998-12-01 | 2006-02-14 | Duke University | Radioconjugation of internalizing antibodies |
US6770445B1 (en) | 1999-02-26 | 2004-08-03 | Pacific Northwest Research Institute | Methods and compositions for diagnosing carcinomas |
EP1169645B1 (en) | 1999-02-26 | 2006-05-31 | Pacific Northwest Research Institute | Methods and compositions for diagnosing carcinomas |
WO2002046765A2 (en) * | 2000-11-08 | 2002-06-13 | Millennium Pharmaceuticals, Inc. | Compositions, kits, and methods for identification, assessment, prevention, and therapy of ovarian cancer |
US20030226155A1 (en) * | 2001-08-30 | 2003-12-04 | Biorexis Pharmaceutical Corporation | Modified transferrin-antibody fusion proteins |
KR20110019357A (ko) * | 2002-08-06 | 2011-02-25 | 더 존스 홉킨스 유니버시티 | 난소암의 검출을 위한 생물 마커의 용도 |
ATE516047T1 (de) * | 2003-05-09 | 2011-07-15 | Diadexus Inc | Ovr110-antikörperzusammensetzungen und anwendungsverfahren |
CN1266475C (zh) * | 2003-06-05 | 2006-07-26 | 马旭 | 一种用于诊断早期卵巢癌的四粘蛋白酶联免疫检测试剂盒 |
US7666583B2 (en) * | 2004-02-19 | 2010-02-23 | Yale University | Identification of cancer protein biomarkers using proteomic techniques |
WO2005098446A2 (en) * | 2004-03-31 | 2005-10-20 | The Johns Hopkins University | Biomarkers for ovarian cancer |
WO2006089125A2 (en) * | 2005-02-16 | 2006-08-24 | Dana-Farber Cancer Institute | Methods of detecting ovarian cancer |
CA2611340A1 (en) * | 2005-06-22 | 2007-01-04 | The Johns Hopkins University | Biomarker for ovarian cancer: ctap3-related proteins |
US8465929B2 (en) * | 2005-06-24 | 2013-06-18 | Vermillion, Inc. | Biomarkers for ovarian cancer |
WO2007081768A2 (en) * | 2006-01-04 | 2007-07-19 | Fujirebio America, Inc. | Use of he4 and other biochemical markers for assessment of ovarian cancers |
-
2007
- 2007-01-04 WO PCT/US2007/000216 patent/WO2007081768A2/en active Application Filing
- 2007-01-04 EP EP11168962A patent/EP2423321A3/en not_active Withdrawn
- 2007-01-04 CN CN201610512072.3A patent/CN106124765A/zh active Pending
- 2007-01-04 EP EP07717842A patent/EP1969136A4/en not_active Withdrawn
- 2007-01-04 EP EP15175155.9A patent/EP3026119B1/en active Active
- 2007-01-04 WO PCT/US2007/000215 patent/WO2007081767A2/en active Application Filing
- 2007-01-04 JP JP2008549562A patent/JP5164855B2/ja active Active
- 2007-01-04 ES ES15175154.2T patent/ES2650244T3/es active Active
- 2007-01-04 EP EP11171015A patent/EP2420576A3/en not_active Withdrawn
- 2007-01-04 CN CN200780007130.6A patent/CN101460630B/zh active Active
- 2007-01-04 PL PL15175154T patent/PL2982761T3/pl unknown
- 2007-01-04 EP EP07717677A patent/EP1846768A4/en not_active Withdrawn
- 2007-01-04 US US11/650,337 patent/US20070286865A1/en not_active Abandoned
- 2007-01-04 ES ES15175155T patent/ES2748397T3/es active Active
- 2007-01-04 JP JP2008549563A patent/JP5221381B2/ja active Active
- 2007-01-04 EP EP15175154.2A patent/EP2982761B1/en active Active
- 2007-01-04 US US11/650,573 patent/US20080020473A1/en not_active Abandoned
- 2007-01-04 CN CN200780007052.XA patent/CN101473041B/zh active Active
-
2012
- 2012-10-12 JP JP2012226640A patent/JP5711196B2/ja active Active
-
2016
- 2016-06-29 HK HK16107583.0A patent/HK1219514A1/zh unknown
-
2018
- 2018-01-29 US US15/882,647 patent/US20180156805A1/en not_active Abandoned
- 2018-02-14 US US15/896,735 patent/US20180180620A1/en not_active Abandoned
-
2020
- 2020-02-04 US US16/781,017 patent/US20200292549A1/en not_active Abandoned
- 2020-02-12 US US16/788,442 patent/US20200182878A1/en not_active Abandoned
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2005501549A (ja) * | 2001-08-29 | 2005-01-20 | パシフィック ノースウエスト リサーチ インスティテュート | 癌腫の診断 |
JP2006515065A (ja) * | 2002-08-16 | 2006-05-18 | ディシジョン バイオマーカーズ インコーポレイテッド | 蛍光配列の読み取り |
Non-Patent Citations (1)
Title |
---|
JPN6011049272; Daniel G. Rosen, Lin Wang, J. Neeley Atkinson, Yinhua Yu, Karen H. Lu, Eleftherios P. Diamandis, Ing: 'Potential makers that complement expression of CA125 in epithelial ovarian cancer' Gynecologic Oncology Vol. 99, pp267-277, 2005 * |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5711196B2 (ja) | 卵巣癌を判定するためのhe4及び他の生化学マーカーの使用 | |
EP2635304B1 (en) | Folate receptor alpha as a diagnostic and prognostic marker for folate receptor alpha-expressing cancers | |
WO2022063156A1 (zh) | 乳腺癌的生物标志物及其应用 | |
JP2013047679A (ja) | 乳がんの評価のためのhe4の使用 | |
EP3102600B1 (en) | Composition and method for detecting malignant neoplastic disease | |
US20240133889A1 (en) | Use of he4 and other biochemical markers for assessment of ovarian cancers | |
US20130095483A1 (en) | Predictive biomarkers for breast cancer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20140218 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20140517 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20140522 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20140618 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20140623 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20140718 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20140724 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140818 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20140819 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20150203 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20150305 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5711196 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |